Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

AHK-Cu vs Syn-Ake

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

AHK-Cu and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

AHK-Cu

Cosmetic Clinical Studies

Syn-Ake

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

AHK-Cu Syn-Ake
Class Copper tripeptide (cosmetic) Cosmetic peptide (snake-venom inspired)
Drug class Dermatologic Dermatologic
Mechanism Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle
Route Topical Topical
Half-life Topical (no systemic) Topical
Dosage (research) Topical 0.01-0.1% Topical 4%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 3 indexed (PubMed 1 · CT 1 · EPMC 1) 5 indexed (PubMed 2 · CT 0 · EPMC 3)
Availability Cosmetic Cosmetic
Reported risks Skin irritation; theoretical copper issues Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick AHK-Cu or Syn-Ake?

AHK-Cu and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.

What is the difference between AHK-Cu and Syn-Ake?

AHK-Cu is classed as Copper tripeptide (cosmetic); Syn-Ake is classed as Cosmetic peptide (snake-venom inspired). Reported mechanism: AHK-Cu, Copper delivery to hair follicles; angiogenesis and VEGF induction in scalp; Syn-Ake, Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle. Reported half-life: AHK-Cu, Topical (no systemic); Syn-Ake, Topical. Routes in published studies: AHK-Cu, Topical; Syn-Ake, Topical.

Which has stronger evidence, AHK-Cu or Syn-Ake?

AHK-Cu and Syn-Ake sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. AHK-Cu is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 3 indexed studies. Syn-Ake is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, AHK-Cu or Syn-Ake?

Neither AHK-Cu nor Syn-Ake is an FDA-approved drug. Catalog status: AHK-Cu, Cosmetic; Syn-Ake, Cosmetic.

Are AHK-Cu and Syn-Ake ever combined?

AHK-Cu and Syn-Ake appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…